Upsher-Smith Completes Acquisition Of Dr Reddy’s Two Migraine Treatments
Upsher-Smith strategically expands and diversifies its portfolio by acquiring Dr Reddy’s two treatments of acute migraine in adults.
You may also be interested in...
Upsher-Smith has strengthened its US generics portfolio with three new launches that will compete in a combined market worth nearly $102.5m.
Sawai’s sales increased on the back of a good performance from recently-launched products in the first nine months of its financial year. However, given the competitive environment the Japanese company is continuing to stick to its full-year forecasts.
Sawai believes the Zembrace and Tosymra sumatriptan brands acquired by its US operation Upsher-Smith could within the next three years bring in more than $50m in annual sales.